{
  "success": true,
  "sourceFile": "C:\\Users\\panik\\Documents\\GitHub\\Protcol2USDMv3\\input\\trial\\NCT04161495_XTEND_1\\NCT04161495_XTEND_1_SAP.pdf",
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36,
    37,
    38,
    39
  ],
  "modelUsed": "gemini-3-flash-preview",
  "sapData": {
    "analysisPopulations": [
      {
        "id": "pop_1",
        "name": "Screened Set",
        "text": "The Screened Set includes all subjects who signed an informed consent form.",
        "populationType": "Other",
        "instanceType": "AnalysisPopulation",
        "label": "SCR",
        "populationDescription": "The Screened Set includes all subjects who signed an informed consent form.",
        "criteria": "Signed informed consent form"
      },
      {
        "id": "pop_2",
        "name": "Full Analysis Set",
        "text": "The Full Analysis Set includes all enrolled subjects who received at least one dose of study drug.",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "FAS",
        "populationDescription": "The Full Analysis Set includes all enrolled subjects who received at least one dose of study drug.",
        "criteria": "Enrolled AND received >=1 dose of BIVV001"
      },
      {
        "id": "pop_3",
        "name": "Safety Analysis Set",
        "text": "The Safety Set consists of all subjects who received at least one dose of study medication.",
        "populationType": "Safety",
        "instanceType": "AnalysisPopulation",
        "label": "SAF",
        "populationDescription": "The Safety Set consists of all subjects who received at least one dose of study medication.",
        "criteria": "Received >=1 dose of BIVV001"
      },
      {
        "id": "pop_4",
        "name": "Pharmacokinetic Analysis Set",
        "text": "Subjects with evaluable PK samples; includes at least 16 participants in Arm A participating in the sequential PK subgroup undergoing extensive PK sampling at Baseline and Week 26, and other participants undergoing abbreviated PK sampling.",
        "populationType": "PK/PD",
        "instanceType": "AnalysisPopulation",
        "label": "PK Set",
        "populationDescription": "Subjects with evaluable PK samples; includes at least 16 participants in Arm A participating in the sequential PK subgroup undergoing extensive PK sampling at Baseline and Week 26, and other participants undergoing abbreviated PK sampling.",
        "criteria": "Received BIVV001 AND has evaluable PK samples"
      },
      {
        "id": "pop_5",
        "name": "Surgery Subgroup",
        "text": "Participants from any arm who undergo major surgery during the study to assess control and prevention of bleeding with BIVV001 treatment in the surgical setting.",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "Surgery",
        "populationDescription": "Participants from any arm who undergo major surgery during the study to assess control and prevention of bleeding with BIVV001 treatment in the surgical setting.",
        "criteria": "Enrolled AND undergo major surgery during study period"
      }
    ],
    "characteristics": [
      {
        "id": "char_1",
        "name": "Age",
        "code": "AGE",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Age",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Age at baseline in years (>=12 years of age for inclusion)"
      },
      {
        "id": "char_2",
        "name": "Endogenous FVIII activity",
        "code": "ENDOGENOUS_FVIII_ACT",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Endogenous FVIII activity",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Baseline endogenous FVIII activity level (severe hemophilia A defined as <1 IU/dL)"
      },
      {
        "id": "char_3",
        "name": "Annualized Bleeding Rate",
        "code": "ANNUALIZED_BLEEDING_",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Annualized Bleeding Rate",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Historical or study-period annualized bleeding rate (ABR)"
      }
    ],
    "summary": {
      "populationCount": 5,
      "characteristicCount": 3
    }
  }
}